| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Oxford Immunotec is seeing positive signs emerging from its strategic partnership with Quest Diagnostics in the US for sales of its interferon-gamma release assay for latent tuberculosis while new initiatives and an overhaul of its China business model are driving international growth.[CR-LF][CR-LF]This week, Oxford Immunotec reported third quarter financial results that beat the analysts' average expectations on both the top and bottom lines. On Tuesday, the maker of the T-Spot.TB test, with headquarters in Abingdon, UK, reported 32 percent growth year over year in total revenue and EPS $.03
Quest Diagnostics today announced that it has achieved Gold status in the American Heart Association's 2019 Workplace Health Achievement Index, ranking the company's workplace health initiative among the best in the nation. 2019 marks the second year in a row that Quest has earned this distinction.[CR-LF][CR-LF]More than 1,000 companies completed the Index assessment this year and those which received Gold recognition have demonstrated the highest level of achievement. The Index uses science-based best practices to evaluate the overall quality and comprehensiveness of workplace health programs.
With simpler acquisitions largely done, the larger labs may be in the next phase of their acquisition strategies — deals that require more labor and sweat.[CR-LF][CR-LF]During Quest Diagnostics' recent Q3 2019 earnings call, Chairman, President, and CEO Steve Rusckowski noted that while the company's lab "acquisition pipeline remains strong … most deals in our pipeline are taking more time to develop than they have in the past."[CR-LF][CR-LF]He cited the greater "complexity" of the acquisitions Quest was currently pursuing, saying that "conversations with hospital systems are getting broader," and added that hospital CEOs are interested in how the company "can help them with professional lab services and taking on more of their reference work."
Construction workers and others handling heavy duty machinery in hazardous conditions are more likely to misuse prescription opioid medication and use cocaine than other workers, according to a study released Thursday.[CR-LF][CR-LF][CR-LF]Earlier this year, Quest Diagnostics DGX, -0.46%, a company performing drug-test laboratory work, said there were double-digit increases in drug detection for six of 17 sectors. The tests look for the presence of drugs, including marijuana, amphetamines, cocaine and opiates.
During its Q3 earnings call last week, Quest Diagnostics provided an update on its plans to move its immunoassays to a single vendor as Chairman, President, and CEO Steve Rusckowski said that the company planned to announce that vendor in the near future.[CR-LF][CR-LF]The move to a single vendor will enable "greater throughput, a more efficient footprint, and is expected to save tens of millions of dollars per year," Rusckowski said, noting that this will help offset declines in test reimbursement due to the Protecting Access to Medicare Act (PAMA).